UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D. C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15 (d) of
                       the Securities Exchange Act of 1934


                         Date of Report: April 30, 1998
                        (Date of earliest event reported)



Commission File Number: 0-18105
                        ------- 


                                VASOMEDICAL, INC.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         DELAWARE                                       11-2871434

(State or other jurisdiction of          (I.R.S. Employer Identification Number)
 incorporation or organization)

180 Linden Avenue, Westbury, New York                     11590
--------------------------------------------------------------------------------
(Address of Principal Executive Offices)            (Zip Code)

Registrant's Telephone Number, Including Area Code  (516) 997-4600
                                                     -------------

--------------------------------------------------------------------------------

(Former name or former address, if changed since last report.)

<PAGE>
Item 5. Other Events

     On April 30, 1998, Vasomedical,  Inc. (the "Company") issued 175,000 shares
of newly created 5% Series C Convertible  Preferred Stock,  $.01 par value, at a
price of $20 per share, for an aggregate of $3,500,000.  The shares were sold to
one (1)  accredited  investor  pursuant to  Regulation D  promulgated  under the
Securities Act of 1933. The Series C Convertible  Preferred Stock is convertible
into Common Stock of the Company at an effective  conversion  price of the lower
of (i)  $2.08,  or (ii) 85% of the  average  closing  bid  price  on the  Nasdaq
SmallCap  Market System of the  Company's  Common Stock for the five (5) trading
days immediately preceding the Date of Conversion, as defined in the Certificate
of Designation of the Series C Convertible  Preferred  Stock attached  hereto as
Exhibit 3.1. In addition, the Investor was issued five-year warrants to purchase
413,712 shares of Common Stock at an exercise price of $2.08 per share.


Item 7. Financial Statements, Pro Forma Information and Exhibits

  (a) and (b) Financial Statements and Pro Forma Information
       None.

  (c) Exhibits


          Exhibit 3.1    Certificate  of  Designation  of  Series  C Convertible
                         Preferred  Stock of Vasomedical, Inc. as filed with the
                         Delaware Secretary of State on May 1, 1998.

          Exhibit 4.1    Purchase  Agreement  between  Vasomedical, Inc. and JNC
                         Opportunity Fund, Ltd., dated as of April 30, 1998.

          Exhibit 4.2    Registration Rights Agreement between Vasomedical, Inc.
                         and JNC Opportunity Fund, Ltd., dated as of April 30,
                         1998.

          Exhibit 4.3    Form of Warrant dated April 30, 1998.

          Exhibit 99.1   Press Release dated May 8, 1998.


<PAGE>
       Pursuant to the requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                VASOMEDICAL, INC.

                           By:  /s/ Anthony Viscusi
                                -------------------
                                Anthony Viscusi
                                President and CEO (Principal Executive
                                Officer)

                                /s/ Joseph A. Giacalone
                                -----------------------
                                Joseph A. Giacalone
                                Treasurer and Secretary (Principal Financial
                                and Accounting Officer)


Date:  May 11, 1998
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 4102}]
{"company-data": {"conformed-name": "VASOMEDICAL INC", "cik": "0000839087", "assigned-sic": "3845", "irs-number": "112871434", "state-of-incorporation": "DE", "fiscal-year-end": "0531"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-18105", "film-number": "98615390"}, "business-address": {"street1": "180 LINDEN AVENUE", "city": "WESTBURY", "state": "NY", "zip": "11590", "phone": "5169974600"}, "mail-address": {"street1": "150 MOTOR PARKWAY", "street2": "SUITE 408", "city": "HAUPPAUGE", "state": "NY", "zip": "11788"}, "former-company": [{"former-conformed-name": "FUTURE MEDICAL PRODUCTS INC /DE/", "date-changed": "19920703"}, {"former-conformed-name": "FUTURE MEDICAL PRODUCTS INC /NY/", "date-changed": "19920506"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D. C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15 (d) of
                       the Securities Exchange Act of 1934

                         Date of Report: April 30, 1998
                        (Date of earliest event reported)

Commission File Number: 0-18105
                        ------- 

                                VASOMEDICAL, INC.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         DELAWARE                                       11-2871434

(State or other jurisdiction of          (I.R.S. Employer Identification Number)
 incorporation or organization)

180 Linden Avenue, Westbury, New York                     11590
--------------------------------------------------------------------------------
(Address of Principal Executive Offices)            (Zip Code)

Registrant's Telephone Number, Including Area Code  (516) 997-4600
                                                     -------------

--------------------------------------------------------------------------------

(Former name or former address, if changed since last report.)
Item 5. Other Events

     On April 30, 1998, Vasomedical,  Inc. (the "Company") issued 175,000 shares
of newly created 5% Series C Convertible  Preferred Stock,  $.01 par value, at a
price of $20 per share, for an aggregate of $3,500,000.  The shares were sold to
one (1)  accredited  investor  pursuant to  Regulation D  promulgated  under the
Securities Act of 1933. The Series C Convertible  Preferred Stock is convertible
into Common Stock of the Company at an effective  conversion  price of the lower
of (i)  $2.08,  or (ii) 85% of the  average  closing  bid  price  on the  Nasdaq
SmallCap  Market System of the  Company's  Common Stock for the five (5) trading
days immediately preceding the Date of Conversion, as defined in the Certificate
of Designation of the Series C Convertible  Preferred  Stock attached  hereto as
Exhibit 3.1. In addition, the Investor was issued five-year warrants to purchase
413,712 shares of Common Stock at an exercise price of $2.08 per share.

Item 7. Financial Statements, Pro Forma Information and Exhibits

  (a) and (b) Financial Statements and Pro Forma Information
       None.

  (c) Exhibits

          Exhibit 3.1    Certificate  of  Designation  of  Series  C Convertible
                         Preferred  Stock of Vasomedical, Inc. as filed with the
                         Delaware Secretary of State on May 1, 1998.

          Exhibit 4.1    Purchase  Agreement  between  Vasomedical, Inc. and JNC
                         Opportunity Fund, Ltd., dated as of April 30, 1998.

          Exhibit 4.2    Registration Rights Agreement between Vasomedical, Inc.
                         and JNC Opportunity Fund, Ltd., dated as of April 30,
                         1998.

          Exhibit 4.3    Form of Warrant dated April 30, 1998.

          Exhibit 99.1   Press Release dated May 8, 1998.
Pursuant to the requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                                VASOMEDICAL, INC.

                           By:  /s/ Anthony Viscusi
                                -------------------
                                Anthony Viscusi
                                President and CEO (Principal Executive
                                Officer)

                                /s/ Joseph A. Giacalone
                                -----------------------
                                Joseph A. Giacalone
                                Treasurer and Secretary (Principal Financial
                                and Accounting Officer)

Date:  May 11, 1998